Wednesday, April 23, 2025

Clade Ia #Monkeypox Virus Linked to Sexual #Transmission, #DRC, August 2024

Abstract

Several concurrent mpox outbreaks are ongoing in the Democratic Republic of the Congo. We report a case of severe clade Ia mpox in an adult woman with indeterminate HIV status who died 16 days after symptom onset. She self-identified as a sex worker and had spent time in the capital city, Kinshasa.

Source: US Centers for Disease Control and Prevention, https://wwwnc.cdc.gov/eid/article/31/5/24-1690_article

____

Mathematical #modelling of in vitro #replication dynamics for multiple highly pathogenic avian #influenza clade 2.3.4.4 viruses in #chicken and #duck cells

Abstract

The introduction and subsequent detection of highly pathogenic avian influenza (HPAI) in poultry is influenced by the virus replication fitness, transmission fitness, and virulence in poultry. These viral fitness parameters are important for implementing surveillance and control measures for poultry. This study investigates the potential application of an avian in vitro model using primary chicken embryo (CEF) and duck embryo fibroblasts (DEF) to identify the viral fitness for a reference panel of eight dominant HPAI clade 2.3.4.4 virus genotypes: four H5N1 viruses isolated between 2021 and 2024, as well as three H5N8 and one H5N6 virus isolated between 2014 and 2020. Infectious virus titre and cytopathogenicity were measured in the primary cell cultures over time and these data were analysed using a mathematical model which delineates cell populations into susceptible, latent, infectious, and dead compartments. In addition to obtaining traditional virological parameters such as peak virus replication and the time to 50% cell death, eight new parameters, key among those, the infecting time (tinf), generation time (tgen) and basic reproduction number (R0), were estimated using the mathematical model. Collectively, these parameters contribute to virus characterization, enhancing the resolution for comparing genetically similar viruses. This approach can allow for the evaluation of virus virulence, replication fitness, and, ideally, transmissibility fitness across different hosts. This study underscores the potential of integrating avian in vitro models with mathematical modeling and builds towards rapid risk assessments of novel HPAI viruses.

Source: BioRxIV, https://www.biorxiv.org/content/10.1101/2025.04.22.649950v1

____

Tuesday, April 22, 2025

Serologic #Surveillance for #Orthoflaviviruses and #Chikungunya Virus in #Bats and #Opossums in #Chiapas, #Mexico

Abstract

We performed serologic surveillance for selected arthropod-borne viruses (arboviruses) in bats and opossums in the Lacandona Rainforest, Chiapas, Mexico, in 2023–2024. Sera were collected from 94 bats of at least 15 species and 43 opossums of three species. The sera were assayed by the plaque reduction neutralization test (PRNT) for antibodies to eight orthoflaviviruses (dengue viruses 1–4, St. Louis encephalitis virus, T’Ho virus, West Nile virus, and Zika virus) and one alphavirus (chikungunya virus; CHIKV). Twelve (12.8%) bats and 15 (34.9%) opossums contained orthoflavivirus-specific antibodies. One bat (a Jamaican fruit bat) was seropositive for Zika virus, and 11 bats contained antibodies to an undetermined orthoflavivirus, as did the 15 opossums. All bats and most opossums seropositive for an undetermined orthoflavivirus had low PRNT titers, possibly because they had been infected with another (perhaps unrecognized) orthoflavivirus not included in the PRNTs. Antibodies that neutralized CHIKV were detected in three (7.0%) opossums and none of the bats. The three opossums had low CHIKV PRNT titers, and therefore, another alphavirus may have been responsible for the infections. In summary, we report serologic evidence of arbovirus infections in bats and opossums in Chiapas, Mexico.

Source: Viruses, https://www.mdpi.com/1999-4915/17/5/590

____

#Lassa Virus #Infection of Primary #Human #Airway Epithelial Cells

Abstract

Lassa mammarenavirus (LASV), a member of the family Arenaviridae, is a highly pathogenic virus capable of causing severe systemic infections in humans. The primary host reservoir is the Natal multimammate mouse (Mastomys natalensis), with human infections typically occurring through mucosal exposure to virus-containing aerosols from rodent excretions. To better understand the molecular mechanisms underlying LASV replication in the respiratory tract, we utilized differentiated primary human airway epithelial cells (HAECs) grown under air–liquid interface conditions, closely mimicking the bronchial epithelium in vivo. Our findings demonstrate that HAECs are permissive to LASV infection and support productive virus replication. While LASV entry into polarized HAECs occurred through both apical and basolateral surfaces, progeny virus particles were predominantly released from the apical surface, consistent with an intrinsic apical localization of the envelope glycoprotein GP. This suggests that apical virus shedding from infected bronchial epithelia may facilitate LASV transmission via airway secretions. Notably, limited basolateral release at later stages of infection was associated with LASV-induced rearrangement of the actin cytoskeleton, resulting in compromised epithelial barrier integrity. Finally, we demonstrate that LASV-infected HAECs exhibited a pronounced type III interferon response. A detailed understanding of LASV replication and host epithelial responses in the respiratory tract could facilitate the development of targeted future therapeutics.

Source: Viruses, https://www.mdpi.com/1999-4915/17/5/592

____

#Vietnam reported one additional #human #infection with avian #influenza virus A #H5N1 (HK CHP, April 22 '25)

Influenza A H5N1, New Cases reported, week 16/2025:

- Date: 18/04/2025;

- Country: Vietnam; 

- Province: Tay Ninh province, Ben Cau district; 

- Sex: Female;

- Age: 8; 

- Clinical condition: Serious;

- Subtype: H5N1.

(...)

Source: Centre for Health Protection, Hong Kong PRC SAR, https://www.chp.gov.hk/files/pdf/2025_avian_influenza_report_vol21_wk16.pdf

____


Monday, April 21, 2025

Molecular and ecological #determinants of #mammalian #adaptability in avian #influenza virus

Abstract

The avian influenza virus (AIV) primarily affects birds and poses an increasing concern due to its growing adaptability to other hosts, heightening zoonotic risks. The adaptability is a key factor in AIV to infect multiple non-avian species, including humans, companion animals, aquatic mammals, carnivores, and other mammals. The virus is evolving through genetic mutations and reassortments, leading to the emergence of AIV strains with enhanced virulence and adaptability in mammals. This highlights the critical need to understand the genetic factors of AIV, including mutations in polymerase proteins, surface antigens, and other regulatory proteins, as well as the dynamics of AIV-host interactions and environmental factors such as temperature, humidity, water salinity, and pH that govern the cross-species adaptability of the virus. This review provides comprehensive insights into the molecular/genetic changes AIV undergoes to adapt in mammalian hosts including bovines, swine, equines, canines, and felines. The adaptive mutations in viral polymerase proteins, such as PB2-E627K, and receptor specificity shift facilitate the virus adaptability in mammals. Since AIVs interact with specific receptors on host cells, therefore the type and distribution of receptors are crucial in determining the host range of the virus and its adaptability by facilitating attachment and entry of the virus. This review examines sialic acid receptor distribution and binding patterns in various mammalian hosts, emphasizing how the presence and structure of specific receptors influence viral interaction, adaptation, and transmission. The review concludes that the differential distribution and expression of SA receptors are vital in the mammalian adaptability and tissue tropism of viral strains. Notably, during the adaptation to mammals, AIVs show a shift in preference from α-2,3 to α-2,6 receptors. This review further emphasizes the role of ecological determinants in the adaptation of viruses to mammalian hosts. Low temperatures, high humidity, and neutral to slightly acidic pH levels enhance virus stability, facilitating its persistence in the environment and spread among susceptible hosts. Overall, AIV remains a global health threat, necessitating coordinated efforts in research, surveillance, and public health strategies.

Source: Infection, https://link.springer.com/article/10.1007/s15010-025-02529-5

____

Exploring influenza A virus receptor distribution in the lactating mammary gland of domesticated livestock and in human breast tissue.

Abstract

The spread of the highly pathogenic avian influenza (HPAI) H5N1 virus among dairy cattle illustrates the adaptability of influenza A viruses (IAV) to infect non-traditional species. While IAV-specific sialic acid (SA) receptors have been identified in the mammary glands of dairy cattle, their presence in pigs, sheep, goats, and alpacas has not been studied until now. The zoonotic transmission of HPAI H5N1 to dairy and poultry farm workers during outbreaks raises public health concerns. This study employed lectin histochemistry to examine the mammary glands of livestock and humans. We found that these tissues were rich in SA α2,6-Gal receptors, followed by SA α2,3-Gal receptors, essential for IAV binding. Notably, the A(H5N1) clade 2.3.4.4b virus could bind to mammary tissue from both cattle and pigs. These findings highlight the potential for HPAI H5N1 to infect and spread within the mammary glands of production animals and humans.

Source: BioRxIV, https://www.biorxiv.org/content/10.1101/2025.04.16.649193v1

____

Sunday, April 20, 2025

#Wastewater #sequencing reveals the #genomic landscape of #Influenza A virus in #Switzerland

Abstract

Influenza A virus poses significant public health challenges, causing seasonal outbreaks and pandemics. Its rapid evolution motivates continuous monitoring of circulating influenza genomes to inform vaccine and antiviral development. Wastewater-based surveillance offers an unbiased, cost-effective approach for genomic surveillance. We developed a novel tiling amplicon primer panel that covers diversity of influenza A virus, targeting segments of the surface proteins HA, NA, and M of subtypes H1N1 and H3N2. Using this panel, we sequenced nucleic acid extracts from 59 Swiss wastewater samples collected at four locations during the 2022/2023 and 2023/2024 winter seasons. We found that wastewater-based abundance estimates of the dominant H1N1 clades correlated with clinical-based estimates in the 2023/2024 season. Furthermore, wastewater-based sequencing revealed mutations in vaccine and drug target sites, consistent with clinical data. Overall, we demonstrate the effectiveness of wastewater-based genomic surveillance of influenza A, including lineage identification and mutation tracking to inform vaccine and antiviral strategies

Source: MedRxIV, https://www.medrxiv.org/content/10.1101/2025.04.17.25325990v1

____

Impacts of high pathogenicity avian #influenza #H5N1 2.3.4.4b south of the #Antarctic Circle

Abstract

High pathogenicity avian influenza (HPAI) H5N1 2.3.4.4b poses a substantial conservation threat to ecosystems, populations, and species globally, with its continued spread into new regions increasing concern for potential ecological consequences. During surveys in February-March 2025, we confirmed the virus presence at the southern extent of its known range along the Western Antarctic Peninsula, with recorded mortalities in South Polar Skuas Stercorarius maccormicki on distinct islands in Marguerite Bay, as well as one confirmed and one suspected case in Kelp Gulls Larus dominicanus. At the time of sampling, no evidence of infection was observed in other seabird or mammal species. Consistent with previous global reports, skuas - here, South Polar Skuas - appear particularly vulnerable, yet broader impacts on the local seabird and mammal community remain unclear. Additionally, our use of rapid antigen tests (VDRG AIV Ag Rapid kit 2.0 Median Diagnostics) in the field demonstrated their potential utility for real-time surveillance, though false negatives (10%) highlight limitations in test sensitivity. These findings contribute to a growing understanding of the impacts of HPAI -H5N1 2.3.4.4b outbreaks on Antarctic species and populations, and will inform continued monitoring, conservation strategies, and biosecurity measures in response to the virus's ongoing spread.

Source: BioRxIV, https://www.biorxiv.org/content/10.1101/2025.04.13.648652v1

____

Saturday, April 19, 2025

Insights into the #clinical and molecular #epidemiology of an infections #outbreak of human #parvovirus B19 in #France, 2023-2024

Highlights

• A large B19V French outbreak of an unexpected magnitude occurred, with a monthly rate that has reached 21.4%.

• During this outbreak, 50% of infected pregnant women exhibited fetal complications.

• Phylogenetic analysis revealed the co-circulation of several B19V lineages of genotype 1a, the main epidemic lineage of which emerged in 2017.


Abstract

Background

The human parvovirus B19 (B19V) infections cycle occurs in 3- to 4-year periods and is responsible for benign childhood erythema infectiosum. It is also associated with transient aplastic crisis in patients with underlying hemolytic diseases and with severe fetal sometimes fatal infection. This study investigated the epidemiological, clinical and molecular characteristics of an unusually large 2023-2024 outbreak of B19V.

Methods.

Laboratory-confirmed cases were retrospectively and prospectively recorded at the Clermont-Ferrand University Hospital, France, between January, 2018 and November, 2023 and between December 2023 and May 2024 (2023/2024), respectively. Demographical and clinical data were investigated for the 2023/2024 period. Subgenome sequences (2,690 nt) were obtained by next generation sequencing for virus genotyping and temporal molecular analysis.

Results

The positive rate of B19V positive laboratory-confirmed cases was seven times higher between December 2023 and May 2024 than in the previous 5-year period (14.6% vs 2.1%, p<0.001). No atypical clinical presentation or increased pathogenicity were observed, but this large outbreak resulted in a higher number of severe infections in pregnant women (8/16, 50.0% of fetal complications) and those with chronic anemia. Phylogenetic analysis revealed that the 2023/2024 outbreak in France and Europe was mainly driven by a pre-existing lineage of B19V 1a subgenotype that emerged in 2017 (95% highest posterior density interval: 2000-2018).

Conclusions

The recent epidemic of B19V infections re-illustrates the immunity gap of the post-pandemic COVID-19 pandemic. This highlight the impact of any outbreak on at-risk population and the need for a more global and genomic surveillance.

Source: Journal of Clinical Virology, https://www.sciencedirect.com/science/article/pii/S138665322500040X?dgcid=rss_sd_all

____

#Coronavirus Disease Research #References (by AMEDEO, April 19 '25)

 


    Am J Respir Crit Care Med

  1. BALTE PP, Kim JS, Sun Y, Allen N, et al
    Associations of Pre-Pandemic Lung Function and Structure with COVID-19 Outcomes: The C4R Study.
    Am J Respir Crit Care Med. 2025 Apr 16. doi: 10.1164/rccm.202408-1656.
    PubMed         Abstract available


    Antiviral Res

  2. KELLY JA, Aida-Ficken V, McMullan LK, Chatterjee P, et al
    Mechanisms of action of repurposed Ebola virus antivirals - the roles of phospholipidosis and cholesterol homeostasis.
    Antiviral Res. 2025 Apr 15:106167. doi: 10.1016/j.antiviral.2025.106167.
    PubMed         Abstract available


    Clin Infect Dis

  3. MESSCHENDORP AL, Zaeck LM, Bouwmans P, van den Broek DAJ, et al
    Replacing Mycophenolate Mofetil by Everolimus in Kidney Transplant Recipients to Increase Vaccine Immunogenicity: Results of a Randomized Controlled Trial.
    Clin Infect Dis. 2025 Apr 15:ciaf107. doi: 10.1093.
    PubMed         Abstract available


    Eur J Radiol

  4. FERRETTI AE, Mercaldo ND, Li X, Rehani MM, et al
    Assessing trends in patients undergoing recurrent CT examinations and cumulative doses.
    Eur J Radiol. 2025;187:112099.
    PubMed         Abstract available


    Int J Infect Dis

  5. CHEN W, Du M, Deng J, Liu M, et al
    Global, regional, and national trends of measles burden and its vaccination coverage among children under five years old: an updated systematic analysis from the Global Burden of Disease study 2021.
    Int J Infect Dis. 2025 Apr 15:107908. doi: 10.1016/j.ijid.2025.107908.
    PubMed         Abstract available


    Intensive Care Med

  6. BOERS LS, van Someren Greve F, van Hattem JM, de Brabander J, et al
    Correction: Pulmonary herpes simplex virus and cytomegalovirus in patients with acute respiratory distress syndrome related to COVID-19.
    Intensive Care Med. 2025 Apr 14. doi: 10.1007/s00134-025-07854.
    PubMed        


    J Med Virol

  7. CHUANG CH, Wang YH, Yeh LT, Yeh CB, et al
    Long-Term Stroke and Mortality Risk Reduction Associated With Acute-Phase Paxlovid Use in Mild-to-Moderate COVID-19.
    J Med Virol. 2025;97:e70351.
    PubMed         Abstract available

  8. SULAIMAN X, Han Y, Liu S, Li K, et al
    Enrichment of G-to-U Substitution in SARS-CoV-2 Functional Regions and Its Compensation via Concurrent Mutations.
    J Med Virol. 2025;97:e70353.
    PubMed         Abstract available


    J Virol

  9. KAWAKITA T, Sekiya T, Kameda Y, Nomura N, et al
    ARNAX is an ideal adjuvant for COVID-19 vaccines to enhance antigen-specific CD4(+) and CD8(+) T-cell responses and neutralizing antibody induction.
    J Virol. 2025 Apr 15:e0229024. doi: 10.1128/jvi.02290.
    PubMed         Abstract available

  10. KRAMMER F, Hermann E, Rasmussen AL
    Highly pathogenic avian influenza H5N1: history, current situation, and outlook.
    J Virol. 2025 Mar 27:e0220924. doi: 10.1128/jvi.02209.
    PubMed         Abstract available

  11. XIE H, Xiong T, Guan J, Han Y, et al
    Induction of mitochondrial damage via the CREB3L1/miR-34c/COX1 axis by porcine epidemic diarrhea virus infection facilitates pathogenicity.
    J Virol. 2025;99:e0059124.
    PubMed         Abstract available

  12. LI Y, Yang S, Qian J, Liu S, et al
    Molecular characteristics of the immune escape of coronavirus PEDV under the pressure of vaccine immunity.
    J Virol. 2025 Apr 16:e0219324. doi: 10.1128/jvi.02193.
    PubMed         Abstract available

  13. COX JB, Nukui M, Murphy EA
    Protein-S-nitrosylation of human cytomegalovirus pp65 reduces its ability to undermine cGAS.
    J Virol. 2025 Apr 17:e0048125. doi: 10.1128/jvi.00481.
    PubMed         Abstract available


    JAMA

  14. MOIN EE, Seewald NJ, Halpern SD
    Use of Life Support and Outcomes Among Patients Admitted to Intensive Care Units.
    JAMA. 2025 Apr 14:e252163. doi: 10.1001/jama.2025.2163.
    PubMed         Abstract available


    Lancet

  15. AMOUZOU A, Barros AJD, Requejo J, Faye C, et al
    The 2025 report of the Lancet Countdown to 2030 for women's, children's, and adolescents' health: tracking progress on health and nutrition.
    Lancet. 2025 Apr 9:S0140-6736(25)00151-5. doi: 10.1016/S0140-6736(25)00151.
    PubMed        


    Nature

  16. BIEVER C
    First global pandemic treaty agreed - without the US.
    Nature. 2025 Apr 16. doi: 10.1038/d41586-025-00839.
    PubMed        

  17. KRAWCZYK PS, Mazur M, Orzel W, Gewartowska O, et al
    Re-adenylation by TENT5A enhances efficacy of SARS-CoV-2 mRNA vaccines.
    Nature. 2025 Apr 16. doi: 10.1038/s41586-025-08842.
    PubMed         Abstract available

  18. DE KEERSMAECKER J, Van Bavel JJ
    Scientists must regain trust.
    Nature. 2025;640:602.
    PubMed        


    Travel Med Infect Dis

  19. FERRIS LJ, Kang J, Rathbone JA, Cruwys T, et al
    Vaccine uptake and adherence to non-pharmaceutical interventions at a youth mass gathering event: A longitudinal field cohort study.
    Travel Med Infect Dis. 2025 Apr 13:102853. doi: 10.1016/j.tmaid.2025.102853.
    PubMed         Abstract available

#Influenza and Other Respiratory Viruses Research #References (by AMEDEO, April 19 '25)

 


    Am J Med

  1. BILC M, Cramer H
    Use of Complementary Medicine Among US Adults with Post-COVID-19: Results from the 2022 National Health Interview Survey.
    Am J Med. 2025;138:862-869.
    PubMed         Abstract available

  2. MAURO M, Cegolon L, Bestiaco N, Zulian E, et al
    Heart Rate Variability Modulation Through Slow-Paced Breathing in Health Care Workers with Long COVID: A Case-Control Study.
    Am J Med. 2025;138:870-883.
    PubMed         Abstract available

  3. NAIK H, Wilton J, Tran KC, Janjua NZ, et al
    Long-Term Health-Related Quality of Life in Working-Age COVID-19 Survivors: A Cross-Sectional Study.
    Am J Med. 2025;138:850-861.
    PubMed         Abstract available

  4. PALACIO A, Bast E, Klimas N, Tamariz L, et al
    Lessons Learned in Implementing a Multidisciplinary Long COVID Clinic.
    Am J Med. 2025;138:843-849.
    PubMed         Abstract available

  5. KRUMHOLZ HM, Sawano M, Bhattacharjee B, Caraballo C, et al
    The PAX LC Trial: A Decentralized, Phase 2, Randomized, Double-blind Study of Nirmatrelvir/Ritonavir Compared with Placebo/Ritonavir for Long COVID.
    Am J Med. 2024 May 10:S0002-9343(24)00271-7. doi: 10.1016/j.amjmed.2024.
    PubMed         Abstract available

  6. SANAL-HAYES NEM, Hayes LD, Mclaughlin M, Berry ECJ, et al
    People with Long COVID and ME/CFS Exhibit Similarly Impaired Dexterity and Bimanual Coordination: A Case-Case-Control Study.
    Am J Med. 2025;138:893-900.
    PubMed         Abstract available


    BMC Pediatr

  7. SINAEI R, Hosseininasab A, Abbaslou P, Zeinali M, et al
    Gastrointestinal and hepatic manifestations among hospitalized COVID-19 children.
    BMC Pediatr. 2025;25:308.
    PubMed         Abstract available


    Epidemiol Infect

  8. ABUCAR EAM, Kern M, Kurth T, Meierkord A, et al
    Health-related quality of life up to 2 years after SARS-CoV-2 infection: a descriptive cohort study.
    Epidemiol Infect. 2025;153:e60.
    PubMed         Abstract available


    J Exp Med

  9. SAIDOUNE F, Lee D, Di Domizio J, Le Floc'h C, et al
    Enhanced TLR7-dependent production of type I interferon by pDCs underlies pandemic chilblains.
    J Exp Med. 2025;222:e20231467.
    PubMed         Abstract available


    J Immunol

  10. MADRID DMC, Gu W, Karim SJI, Lowke MT, et al
    Single-cell analysis of pig lung leukocytes and their response to influenza infection and oseltamivir therapy.
    J Immunol. 2025 Apr 15:vkaf032. doi: 10.1093.
    PubMed         Abstract available


    J Infect Dis

  11. MORRIS SE, Mathis SM, Reeves E, Chung JR, et al
    Modeling the Potential Impacts of Outpatient Antiviral Treatment in Reducing Influenza-Associated Hospitalizations in the United States.
    J Infect Dis. 2025 Apr 12:jiaf061. doi: 10.1093.
    PubMed         Abstract available

  12. CORTIER T, Gilboa M, Layan M, Joseph G, et al
    Factors Associated With the Transmission of the Delta Severe Acute Respiratory Syndrome Coronavirus 2 Variant in Households: The Israeli COVID-19 Family Study (ICoFS).
    J Infect Dis. 2025;231:e734-e742.
    PubMed         Abstract available

  13. KOZANLI E, Winkel AMAM, Han AX, van den Brink S, et al
    Shortened SARS-CoV-2 Viral RNA Shedding in Saliva During Early Omicron Compared to Wild-Type Pandemic Phase.
    J Infect Dis. 2025;231:940-945.
    PubMed         Abstract available

  14. CHALKIAS S, Pragalos A, Akinsola A, Berman G, et al
    Safety and Immunogenicity of SARS-CoV-2 Spike Receptor-Binding Domain andN-Terminal Domain mRNA Vaccine.
    J Infect Dis. 2025 Jan 10:jiaf022. doi: 10.1093.
    PubMed         Abstract available

  15. FELDSTEIN LR, Ruffin J, Wiegand RE, Borkowf CB, et al
    Effectiveness of mRNA COVID-19 vaccines and hybrid immunity in preventing SARS-CoV-2 infection and symptomatic COVID-19 among adults in the United States.
    J Infect Dis. 2025 Jan 8:jiaf007. doi: 10.1093.
    PubMed         Abstract available

  16. DOLANGE V, Slamanig S, Abdeljawad A, Lai TY, et al
    A Surrogate Enzyme-Linked Immunosorbent Assay to Select High-Titer Human Convalescent Plasma for Treating Immunocompromised Patients Infected With Severe Acute Respiratory Syndrome Coronavirus 2 Variants of Concern.
    J Infect Dis. 2025;231:e723-e733.
    PubMed         Abstract available

  17. ALESSANDRINI J, Smith BT, Fitzpatrick T, Buchan SA, et al
    Socioeconomic Inequities in the Age-Specific Burden of Severe Respiratory Syncytial Virus in Canada, 2016-2019.
    J Infect Dis. 2025;231:e626-e637.
    PubMed         Abstract available

  18. JACOBS MB, Clark AE, Goldhaber NH, Valentine HD, et al
    Antibody Levels From High-Throughput Variant-Specific SARS-CoV-2 Anti-Spike Immunoglobulin G and Angiotensin-Converting Enzyme 2 Neutralization Assays Correlate With COVID-19 Infection Risk in a Large Population.
    J Infect Dis. 2025;231:921-930.
    PubMed         Abstract available

  19. SANKARANARAYANAN R, Ha B, Sun H, Liu K, et al
    Evaluation of Immunoglobulin A Enzyme Immunoassays to Detect Primary Respiratory Syncytial Virus Infection in Infants and Young Children.
    J Infect Dis. 2025;231:1060-1068.
    PubMed         Abstract available

  20. CHO HK, Frivold C, Chu HY
    Maternal Immunization.
    J Infect Dis. 2025;231:830-836.
    PubMed         Abstract available


    J Virol

  21. HU H, Zhang Y, Zheng H, Zhao X, et al
    Thymic stromal lymphopoietin improves protective immunity of the SARS-CoV-2 subunit vaccine by inducing dendritic cell-dependent germinal center response.
    J Virol. 2025 Mar 4:e0232324. doi: 10.1128/jvi.02323.
    PubMed         Abstract available

  22. KARL V, Hofmann M, Thimme R
    Role of antiviral CD8+ T cell immunity to SARS-CoV-2 infection and vaccination.
    J Virol. 2025 Mar 3:e0135024. doi: 10.1128/jvi.01350.
    PubMed         Abstract available

  23. LOWEN AC, Baker AL, Bowman AS, Garcia-Sastre A, et al
    Pandemic risk stemming from the bovine H5N1 outbreak: an account of the knowns and unknowns.
    J Virol. 2025;99:e0005225.
    PubMed         Abstract available

  24. SIMS A, Weir DJ, Cole SJ, Hutchinson E, et al
    SARS-CoV-2 cellular coinfection is limited by superinfection exclusion.
    J Virol. 2025 Mar 21:e0207724. doi: 10.1128/jvi.02077.
    PubMed         Abstract available

  25. DADONAITE B, Burrell AR, Logue J, Chu HY, et al
    SARS-CoV-2 neutralizing antibody specificities differ dramatically between recently infected infants and immune-imprinted individuals.
    J Virol. 2025 Mar 25:e0010925. doi: 10.1128/jvi.00109.
    PubMed         Abstract available

  26. JOHN K, Huntress I, Smith E, Chou H, et al
    Human long noncoding RNA VILMIR is induced by major respiratory viral infections and modulates the host interferon response.
    J Virol. 2025 Mar 25:e0014125. doi: 10.1128/jvi.00141.
    PubMed         Abstract available

  27. LI P, Faraone JN, Hsu CC, Chamblee M, et al
    Role of glycosylation mutations at the N-terminal domain of SARS-CoV-2 XEC variant in immune evasion, cell-cell fusion, and spike stability.
    J Virol. 2025 Mar 26:e0024225. doi: 10.1128/jvi.00242.
    PubMed         Abstract available

  28. JANA ID, Kanjo K, Roy S, Bhasin M, et al
    Early 2022 breakthrough infection sera from India target the conserved cryptic class 5 epitope to counteract immune escape by SARS-CoV-2 variants.
    J Virol. 2025 Mar 26:e0005125. doi: 10.1128/jvi.00051.
    PubMed         Abstract available


    J Virol Methods

  29. CHANG C, Li L, Guo Y, Ji L, et al
    The potential application of digital PCR in detecting different SARS-CoV-2 viral loads.
    J Virol Methods. 2025;335:115151.
    PubMed         Abstract available

  30. DE BEER C, Vanmali HD
    Genotypic analysis of rhinovirus and human respiratory syncytial virus in sudden unexpected death in infancy cases at Tygerberg Hospital, Cape Town, South Africa.
    J Virol Methods. 2025;335:115150.
    PubMed         Abstract available

  31. ZARGAR B, Sattar SA, McKinney J, Ijaz MK, et al
    The stability and elimination of mammalian enveloped and non-enveloped respiratory and enteric viruses in indoor air: Testing using a room-sized aerobiology chamber.
    J Virol Methods. 2025;335:115144.
    PubMed         Abstract available

  32. REYNA RA, Walker J, Viveros A, Mitchell B, et al
    Optimization of a panel of behavioral tests for use in containment using a golden Syrian hamster model.
    J Virol Methods. 2025;335:115132.
    PubMed         Abstract available


    Minerva Pediatr (Torino)

  33. PECORARO L, Castagnoli R, Salemi C, Piacentini G, et al
    The "stay at home" COVID-19 lockdown restriction may have prevented asthma exacerbations in children affected by pollen allergy: a single center experience.
    Minerva Pediatr (Torino). 2025;77:139-142.
    PubMed         Abstract available

  34. SODERO G, Talloa D, Cipolla C
    GH therapy in children and adolescents with growth hormone deficiency during the first phase of COVID-19 lockdown: a survey in an Italian center.
    Minerva Pediatr (Torino). 2025;77:148-153.
    PubMed         Abstract available

  35. TESARI CRNKOVIC H, Bendelja K, Gjergja Juraski R, Turkalj M, et al
    Respiratory syncytial virus specific immunoglobulin G4 antibodies and atopic diseases in children.
    Minerva Pediatr (Torino). 2025;77:130-138.
    PubMed         Abstract available


    PLoS Comput Biol

  36. POZZATI G, Flores SC
    Combining flipped-classroom and spaced-repetition learning in a master-level bioinformatics course.
    PLoS Comput Biol. 2025;21:e1012863.
    PubMed         Abstract available


    PLoS One

  37. IWU CD, Shrestha P, Littman AJ, Hood JE, et al
    The association between healthcare access and shingles vaccination among older adults in Virginia, United States.
    PLoS One. 2025;20:e0316429.
    PubMed         Abstract available

  38. STRICKLING M, Zarif N, Nguyen H, Moradi Khalaj S, et al
    A comparison of fit, heat stress, oxygen saturation and comfort between a novel reusable mask and disposable N95 respirator.
    PLoS One. 2025;20:e0321538.
    PubMed         Abstract available

  39. AGUIRRE-MILACHAY E, Leon-Figueroa DA, Diaz-Velez C, Valladares-Garrido MJ, et al
    Factors associated with the survival of adults with COVID-19 using a high-flow nasal cannula in a tertiary hospital in northern Peru during the second wave of the pandemic.
    PLoS One. 2025;20:e0309855.
    PubMed         Abstract available

  40. VILLOTA SD, Veloz-Villavicencio E, Garcia-Iturralde S, Arevalo JV, et al
    Validation of new equipment for SARS-CoV-2 diagnosis in Ecuador: Detection of the virus and antibodies generated by disease and vaccines with one POC device.
    PLoS One. 2025;20:e0321794.
    PubMed         Abstract available

  41. PARKINSON C, Shen X, MacDonald M, Logan SW, et al
    Outdoor recreation's association with mental health and well-being during the COVID-19 pandemic.
    PLoS One. 2025;20:e0321278.
    PubMed         Abstract available

  42. SUSLOW A, Schlossler K, Chikhradze N, Lauer R, et al
    Should I stay or should I go-Medical assistants experiences and coping with patient demand and lack of appreciation during the Covid-19 pandemic.
    PLoS One. 2025;20:e0320953.
    PubMed         Abstract available

  43. LEISER R, McLeod J, Mapp F, Stirrup O, et al
    Insights into the implementation of a whole genome sequencing report form (SRF) to reduce nosocomial SARS-CoV-2 in UK hospitals within an unfolding pandemic: A qualitative process evaluation using normalisation process theory.
    PLoS One. 2025;20:e0321534.
    PubMed         Abstract available

  44. CILOVIC-LAGARIJA S, Eitze S, Skocibusic S, Musa S, et al
    Behavioral insights during the COVID-19 pandemic in the Federation of Bosnia and Herzegovina: the role of trust, health literacy, risk and fairness perceptions in compliance with public health and social measures.
    PLoS One. 2025;20:e0320433.
    PubMed         Abstract available

  45. QUINTERO-RINCON A, Di-Pasquale R, Quintero-Rodriguez K, Batatia H, et al
    Computer-based quantitative image texture analysis using multi-collinearity diagnosis in chest X-ray images.
    PLoS One. 2025;20:e0320706.
    PubMed         Abstract available


    Proc Natl Acad Sci U S A

  46. RIOS CARRASCO M, Lin TH, Zhu X, Gabarroca Garcia A, et al
    The Q226L mutation can convert a highly pathogenic H5 2.3.4.4e virus to bind human-type receptors.
    Proc Natl Acad Sci U S A. 2025;122:e2419800122.
    PubMed         Abstract available

  47. HUANG QJ, Kim R, Song K, Grigorieff N, et al
    Virion-associated influenza hemagglutinin clusters upon sialic acid binding visualized by cryoelectron tomography.
    Proc Natl Acad Sci U S A. 2025;122:e2426427122.
    PubMed         Abstract available


    Vaccine

  48. TONG F, Zhou T, Tang L, Wu X, et al
    Evaluating the impact of influenza vaccine on preventing stroke hospitalization and death in Chinese elderly hypertensive patients: A retrospective cohort study.
    Vaccine. 2025;54:127004.
    PubMed         Abstract available


    Virology

  49. BEAUDOIN-BUSSIERES G, Tauzin A, Dionne K, El Ferri O, et al
    Multiple exposures to SARS-CoV-2 Spike enhance cross-reactive antibody-dependent cellular cytotoxicity against SARS-CoV-1.
    Virology. 2025;607:110512.
    PubMed         Abstract available

  50. ANDERSON M, Lopez J, Wyr M, Ramirez PW, et al
    Defining diverse spike-receptor interactions involved in SARS-CoV-2 entry: Mechanisms and therapeutic opportunities.
    Virology. 2025;607:110507.
    PubMed         Abstract available

  51. CHAKRABORTY C, Bhattacharya M, Abdelhameed AS
    Recent SARS-CoV-2 evolution trajectories indicate the emergence of Omicron's several subvariants and the current rise of KP.3.1.1 and XEC.
    Virology. 2025;607:110508.
    PubMed         Abstract available


    Virus Res

  52. ZHAO X, Zhu X, Wang J, Ye C, et al
    The epidemiological analysis of respiratory virus infections in Children in Hangzhou from 2019 to 2023.
    Virus Res. 2025;355:199558.
    PubMed         Abstract available

  53. ZADEH VR, Lew JM, Zahoor MA, Santer D, et al
    Combination therapy enhances the antiviral activity of IFN-lambda against SARS-CoV-2 and MERS-CoV.
    Virus Res. 2025;355:199560.
    PubMed         Abstract available

  54. YAN J, Liu F, Hu S, Pan J, et al
    Regional dynamics and mechanisms behind SARS-CoV-2 XDV.1 prevalence in Chongqing via genomic surveillance and molecular insights.
    Virus Res. 2025;355:199562.
    PubMed         Abstract available

  55. YANG W, Tao T, Zhang J, Yao Y, et al
    The association of cycle threshold value with clinical features in patients infected with Omicron variant.
    Virus Res. 2025;355:199565.
    PubMed         Abstract available

Emerging #zoonotic potential of #H4N1 avian #influenza virus: enhanced #human #receptor binding and #replication via novel mutations

Abstract

Background

Avian influenza virus (AIV), a zoonotic pathogen found worldwide, includes multiple subtypes, one of which is the H4 subtype frequently detected in wild birds and poultry. Despite its prevalence, research on H4 subtype AIV has been scarce, with a focus predominantly on the H4N2 and H4N6 subtypes. The zoonotic potential of H4N1 has not been investigated to date.

Methods

In this study, we used gene sequencing in conjunction with bioinformatics methodologies to analyze wild-type H4N1 AIV strain and mutant strains emerging from serial passaging in cell culture. Furthermore, we assessed the zoonotic potential of H4N1 and the alterations caused by mutations via a series of phenotype assays, including evaluation of receptor binding affinity, immunofluorescence assays, analyses of growth kinetics across different animal cell cultures, and in vivo pathogenicity studies.

Results

Our research reveals that H4N1 AIV can bind to human receptors and exhibits an affinity for human lung and tracheal tissues. In vitro experiments demonstrate that H4N1 replicates efficiently in human cell lines. Furthermore, animal studies demonstrate that H4N1 can induce pneumonia in mice without the need for prior adaptation to the host. Notably, during passage in cell culture, H4N1 rapidly acquired two previously unreported mutations. These mutations significantly enhanced the virus’s ability to attach to human receptors and its capacity for replication.

Conclusions

In summary, our study provides preliminary experimental evidence for the emerging zoonotic potential of H4N1 AIV. These findings expand our knowledge of the H4 subtype AIV and reinforce the critical need for continued surveillance of AIV to prevent and prepare for potential outbreaks affecting human health.

Source: Virology Journal, https://virologyj.biomedcentral.com/articles/10.1186/s12985-025-02736-4

____

Sustained cross-species #transmission of #gammacoronavirus in wild #birds reveled by viral characterization in #China

Abstract

Gammacoronavirus (γ-CoV) primarily infects poultry, wild birds, and marine mammals. The widespread distribution and circulation of γ-CoV in the ecological environment may lead to sustained transmission and economic loss. To better understand the diversity of γ-CoV in wild birds, we collect 482 wild-bird fecal samples from Yunnan, encompassing fourteen bird species. We detected twelve γ-CoV positive samples in five bird species, with the characterization of five complete genomes - HNU5-1, HNU5-2, HNU5-3, HNU6-1, and HNU6-2-indicating that these genomes represent two viral species. The HNU5 strains were derived from Black-headed gull (Chroicocephalus ridibundus), while the HNU6 strains were came from Mallard (Anas platyrhynchos), and both of those were recombinant. The HNU5 strain exhibited the highest sequence identity (95.45%) with a γ-CoV strain isolated from Numenius phaeopus (GenBank accession: PP845452). Similarly, the HNU6 strain showed 95.18% nucleotide identity with a γ-CoV strain (GenBank accession: PP845437) derived from Anas platyrhynchos. Taxonomic analysis confirmed that HNU6s belong to the Gammacoronavirus anatis species, while HNU5s attributed to a new species. Cross-species analysis revealed active host-switching events among γ-CoVs, indicating potential transmission of γ-CoVs from marine mammals to wild bird, from wild bird to poultry, and inter-wild bird and inter-poultry transmission. In summary, we report five new γ-CoV strains in wild birds and outline the cross-species transmission of γ-CoVs. Our findings link γ-CoV hosts across different natural environments and provide new insights for exploring γ-CoVs.

Source: BioRxIV, https://www.biorxiv.org/content/10.1101/2025.04.17.648926v1

____

Friday, April 18, 2025

Detection of Avian #Influenza Virus in #Pigeons

Abstract

Pigeons (Columba livia) are usually kept as free-ranging or racing birds, and they have direct contact with livestock, poultry, and humans. Therefore, they may have an important role in the ecology of influenza virus among various species. In the present study, we bring together all available sequence data of pigeon avian influenza virus (AIV) from public databases to address the current understanding of the genomic characteristics and emergence of each subtype of AIV in pigeons. Collectively, we identified 658 pigeon AIV strains in 21 countries across the world, which were mainly distributed in Europe, Asia, and North America. H1 (2), H2 (1), H3 (8), H5 (71), H6 (16), H7 (16), H9 (543), and H11 (1) AIV subtypes have been identified in pigeons. In addition, we interrogate features of the H5, H6, H7, and H9 subtypes of pigeon AIV, which are relatively common in pigeons. It is particularly noteworthy that the H5 AIV strains identified in pigeons are all classified as HPAIV. For the first time, this study presents a complete overview of the multiple AIV subtypes that have been circulating in pigeons, providing information on their distribution and genomic characteristics. This study will help to understand the molecular evolution of AIV in pigeons.

Source: Viruses, https://www.mdpi.com/1999-4915/17/4/585

____

#Liberia - High pathogenicity avian #influenza #H5N1 viruses (poultry) (Inf. with) - Immediate notification

 


A poultry farm in Totota, right behind the Lutheran football field in Bong County.

Source: WOAH, https://wahis.woah.org/#/in-review/6432

____

#USA, Monitoring for Avian #Influenza A(#H5) Virus In #Wastewater (as of April 18 '25)



{Excerpt}

Time Period: April 06, 2025 - April 12, 2025

-- H5 Detection3 sites (0.9%)

-- No Detection348 sites (99.1%)

-- No samples in last week243 sites

(...)




Source: US Centers for Disease Control and Prevention, https://www.cdc.gov/bird-flu/h5-monitoring/index.html?cove-tab=0

____

#Chikungunya virus virus-like particle #vaccine #safety and immunogenicity in adults older than 65 years: a phase 3, randomised, double-blind, placebo-controlled trial

Summary

Background

Adults older than 65 years are at increased risk for atypical presentations of chikungunya disease, as well as for severe outcomes including death.

Methods

In this phase 3, randomised, double-blind, placebo-controlled, parallel-group trial, adults aged 65 years and older received a single intramuscular dose of Vimkunya (previously chikungunya virus virus-like particle vaccine) or placebo at ten sites in the USA. Participants, clinical site personnel, and the sponsor were masked to individual treatment assignments until all participants had completed their involvement in the trial and the database was cleaned and locked. Baseline and postvaccination chikungunya virus serum neutralising antibody (SNA) titres (NT80) were assessed at selected timepoints. Safety was assessed up to 183 days after dose administration in all participants from the exposed population who provided safety assessment data. This trial is registered with ClinicalTrials.gov, NCT05349617, and is completed.

Findings

Between May 12 and Dec 2, 2022, 413 participants were recruited and randomly assigned (1:1) to receive the Vimkunya vaccine (n=206) or placebo (n=207). The coprimary endpoints of immunologic superiority of chikungunya virus SNA titres compared with placebo and geometric mean titre at day 22 were met. Vimkunya induced a protective seroresponse (SNA NT80≥100, considered the presumptive seroprotective antibody response) in 149 (82%) of 181 participants (95% CI 76·1–87·2) at day 15, in 165 (87%) of 189 participants (81·8–91·3) at day 22, and in 139 (76%) of 184 participants (68·9–81·2) at day 183. Although there was a slightly higher early immune response in the 65–74 years age group at day 15 compared with the 75 years and older age group, the seroresponse rates at day 22 and day 183 were similar. There were no notable differences in adverse event rates between groups, and most adverse events were grade 1 or 2 in severity and of short duration. No vaccine-related serious adverse events or deaths occurred.

Interpretation

We provide robust data from adults aged 65 years and older showing that Vimkunya is well tolerated and can provide a high rate of protection within 2 weeks postvaccination and during 6 months of follow-up.

Source: The Lancet, https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)00372-1/abstract?rss=yes

____

Estimates of #epidemiological #parameters for #H5N1 #influenza in #humans: a rapid review

Abstract

Background 

The ongoing H5N1 panzootic in mammals has amplified zoonotic pathways to facilitate human infection. Characterising key epidemiological parameters for H5N1 is critical should it become widespread. 

Aim 

To identify and estimate critical epidemiological parameters for H5N1 from past and current outbreaks, and to compare their characteristics with human influenza subtypes and the 2003 Netherlands H7N7 outbreak . 

Methods 

We searched PubMed, Embase, and Cochrane Library for systematic reviews reporting parameter estimates from primary data or meta-analyses. To address gaps, we searched PubMed and Google Scholar for studies of any design providing relevant estimates. We estimated the basic reproduction number for the outbreak in the US and the 2003 Netherlands H7N7 outbreak. In addition we estimated the serial interval for H5N1 using data from previous household clusters in Indonesia. We also applied a branching process model to simulate transmission chain size and duration to assess if simulated transmission patterns align with observed dynamics. 

Results 

From 46 articles, we identified H5N1s epidemiological profile as having lower transmissibility (R0 < 0.2) but higher severity compared to human subtypes. Evidence suggests H5N1 has a longer incubation (~4 days vs ~2 days) and serial intervals (~6 days vs ~3 days) than human subtypes, impacting transmission dynamics. The epidemiology of the US H5 outbreak is similar to the 2003 Netherlands H7N7 outbreak. Key gaps remain regarding latent and infectious periods. 

Conclusions 

We characterised critical epidemiological parameters for H5N1 infection. The current U.S. outbreak shows lower pathogenicity but similar transmissibility compared to prior outbreaks. Longer incubation and serial intervals may enhance contact tracing feasibility. These estimates offer a baseline for monitoring changes in H5N1 epidemiology.

Source: MedRxIV, https://www.medrxiv.org/content/10.1101/2024.12.11.24318702v3

____

Thursday, April 17, 2025

Towards #diagnostic #preparedness: detection of #HPAI A(#H5N1) in contrived nasal #swab #specimens using rapid #antigen and point-of-care molecular tests

Abstract

Highly pathogenic avian influenza (HPAI) A(H5N1) clade 2.3.4.4b was first detected in birds in the United States in 2021 and an ongoing outbreak in dairy cattle began in early 2024. At least 70 U.S. cases have been identified in humans with exposure to infected cattle, poultry, and wild birds. No human-to-human transmission has been documented. However, as part of diagnostic preparedness, we evaluated the ability of currently available influenza tests to detect 2024 U.S. H5N1 strains. Contrived nasal swab samples were prepared using live or inactivated 2024 H5N1 and used to test twelve rapid antigen tests (lateral flow assays, or LFA), including 10 commercially-available influenza A LFAs and two H5-specific LFAs. Five point-of-care (POC) molecular assays were also tested. An inclusivity testing protocol was used, wherein a predetermined dilution series is used to evaluate each assay, enabling head-to-head comparison of assay performance. All lateral flow assays and POC molecular tests were able to detect bovine 2024 H5N1 (genotype B3.13). Sensitivity for the POC molecular tests (heat-inactivated virus) ranged from 1.55 to 7.75 TCID50/swab. For 11/12 LFAs, including 10 commercial influenza A tests and an RUO H5 assay, sensitivity (live virus) ranged from 78-1550 TCID50/swab. Testing of four LFAs confirmed inclusivity for a genotype D1.1 strain. Available rapid antigen and point-of-care molecular influenza tests can detect 2024 U.S. H5N1 strains in contrived samples, with a wide range of analytical sensitivity. In the event of human-to-human transmission, clinical performance and optimal sample types would need to be established.

Source: MedRxIV, https://www.medrxiv.org/content/10.1101/2025.04.15.25325613v1

____

My New Space

Most Popular Posts